The big picture: Magnitude Biosciences, a specialist contract research organisation (CRO) and Durham University spinout, secured €1.5 million in funding to accelerate the commercialization of VivoScan, its proprietary in vivo high-throughput screening (HTS) platform.
Why it matters:
- Accelerated Discovery: The investment enables Magnitude Biosciences to advance its VivoScan platform, aiming to screen millions of compounds in whole organisms, significantly speeding up drug discovery.
- Preclinical Efficiency: The platform offers a more comprehensive understanding of drug effects earlier in development by using living biological models, which is crucial for complex areas like aging and neurodegenerative diseases.
- Market Trend: The funding aligns with a broader trend of investment in European platforms focused on improving the speed and quality of preclinical drug discovery.
How it works:
- Whole Organism Screening: VivoScan utilizes tiny C. elegans worms to evaluate how a complete organism responds to potential treatments, moving beyond isolated cell or molecular analysis.
- Automated Analysis: The platform integrates automated imaging, robotics, and AI to rapidly and thoroughly analyze these biological responses.
- Rich Data Generation: VivoScan generates detailed, whole-organism biological data, providing insights into how therapies impact health, aging, and disease, thereby helping identify better drug candidates.
The catch: The preclinical drug discovery market is increasingly competitive, with numerous European startups securing funding for diverse high-throughput screening, organoid, and AI-driven platforms. Magnitude Biosciences will need to demonstrate clear differentiation and superior efficacy of its ‘C. elegans’-based approach to capture significant market share amidst this crowded landscape.
Key Facts
- Company: Magnitude Biosciences
- Amount: €1.5M
- Investors: Northstar Ventures (lead), Maven, Angel investors
- Founder: Dr. Fozia Saleem
- Sector: Drug Discovery
- Headquarters: Durham, UK
